To our knowledge, this is the first study elucidating the correlation of GSTT1, GSTM1, and TNF-polymorphisms with the risk and the outcome of MM, as well as with response to bortezomib under in vitro conditions. The gene discussed is GSTM1; the disease is Miyoshi myopathy.